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Abstract
Human African trypanosomiasis (HAT) is a deadly vector-born disease caused by an extracellular parasite, the trypanosome.
Little is known about the cellular immune responses elicited by this parasite in humans. We used multiparameter flow
cytometry to characterize leukocyte immunophenotypes in the blood and cerebrospinal fluid (CSF) of 33 HAT patients and
27 healthy controls identified during a screening campaign in Angola and Gabon. We evaluated the subsets and activation
markers of B and T lymphocytes. Patients had a higher percentage of CD19
+ B lymphocytes and activated B lymphocytes in
the blood than did controls, but lacked activated CD4+ T lymphocytes (CD25
+). Patients displayed no increase in the
percentage of activated CD8+ T cells (HLA-DR
+, CD69
+ or CD25
+), but memory CD8 T-cell levels (CD8
+CD45RA
2) were
significantly lower in patients than in controls, as were effector CD8 T-cell levels (CD8
+CD45RA
+CD62L
2). No relationship
was found between these blood immunophenotypes and disease severity (stage 1 vs 2). However, CD19
+ B-cell levels in the
CSF increased with disease severity. The patterns of T and B cell activation in HAT patients suggest that immunomodulatory
mechanisms may operate during infection. Determinations of CD19
+ B-cell levels in the CSF could improve disease staging.
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Introduction
Human African trypanosomiasis (HAT) is caused by Trypano-
soma brucei (T. b.) gambiense in West and Central Africa, and by T. b.
rhodesiense in East and Southern Africa. Epidemics of the disease
occur, with the Democratic Republic of Congo, Angola and
Sudan the most afflicted countries in recent years [1]. Disease
control is based on the implementation of appropriate public
health policies, which remains difficult in countries with limited
resources subject to political unrest. Humans contract the disease
after being bitten by an infected tse-tse fly. The trypanosomes
move out from the site of inoculation, invading all parts of the
body via the bloodstream and lymphatic system (stage 1). The
encephalitic stage (stage 2) begins when parasites cross the blood-
brain barrier, modifying sleep-wake cycles, endocrinological
functions and behavior. Over time, the entire central nervous
system (CNS) may be affected, with sensory and motor
dysfunctions progressively leading to irreversible demyelinating
disease [2]. It has been suggested that an autoimmune response
against neuronal and myelin antigens occurs in cases of CNS
involvement. Indeed, autoantibodies reacting with galactocerebro-
sides [3], the major components of myelin, and with neurofila-
ments [4], the intermediate filaments of neurons, have been
reported. The time-course of the disease varies widely due to the
complexities of the host-parasite interaction, resulting in immune
system-driven mechanisms with both beneficial and deleterious
effects on the body [5–6]. The immunophenotyping of lympho-
cytes in patients with viral infections, immunodeficiencies and
autoimmune diseases has provided clues to the pathogenesis of
these diseases [7–8]. Furthermore, the patterns of lymphocyte
activation observed during the course of Chagas’ disease, caused
by a trypanosome endemic in South America (Trypanosoma cruzi),
may provide an explanation for the cardiac disease occurring
during infection [9–10]. In HAT, the mechanisms of host-parasite
interaction and the subsequent development of a demyelinating
disease in the CNS are not well understood. Classically and
alternatively activated macrophages play a key role in initiating the
immune response and disease control [11–13]. Indeed, the
protection of the host against lesion formation depends on the
ability to downregulate alternatively activated macrophages. The
subsequent stages of cellular immune profile during the course of
the disease have not been extensively studied in humans and
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6184remain unclear. We therefore carried out a clinical study with the
aim of describing the phenotypic changes occurring in subsets of
lymphocyte during HAT.
Results
Enrollment of patients and clinical data
Survey 1 was performed in November 2002 in Angola (Viana
and Bengo districts) and in Gabon (N’kembo Hospital). Blood
samples from 17 patients (16 Angolans, 1 Gabonese) and 13
controls (Gabonese from N’kembo) were analyzed. Survey 2 was
performed in June 2004 in Angola (Bengo district) and Gabon
(Estuaire district). Blood samples from 16 Angolan patients and 14
controls (6 Gabonese, 8 Angolans) were analyzed. All subjects
belonged to the Bantu ethnic group and were of similar
socioeconomic status. They were matched for age and sex with
controls whenever possible. The epidemiological and clinical
characteristics and disease stages of the patients are summarized in
Table 1. Briefly, clinical and biological data allowed us to identify
17 patients in stage 2 (S2), 11 patients in stage 1 (S1) and 9 patients
in intermediate stage (S-int) as defined in material and methods
below.
Blood lymphocyte subset profiles
B and T cell activation markers in blood. The general
profile of lymphocyte subsets common to both surveys (CD19,
CD3, CD4, CD8) is presented in figure 1 for 33 HAT patients and
27 controls. Patients had significantly larger numbers of B (CD19
+)
cells (Table 2) and significantly fewer T (CD3
+) cells (Figure 1)
than controls (P=0.003 and 0.04, respectively). The CD4/CD8
ratios of patients and controls were similar (Table 3). Lymphocyte
subsets did not differ significantly between S-1, S-int and S-2
patients (P.0.05).
The results for B cells (CD19
+) in 33 patients and 27 controls
(survey 1 and 2) and for B-cell activation markers (CD69
+, CD95
+)
in 16 patients and 14 controls (survey 2) are presented in Table 2.
Patients displayed significantly stronger expression of B-cell
activation markers than did controls (P=0.03 and 0.0001,
respectively).
The results for CD4
+ and CD8
+ T cells (CD3
+) in 33 patients
and 27 controls (surveys 1 and 2) and for T-cell activation markers
are presented in Table 3. The results for lymphocyte markers
analyzed exclusively in survey 1 (CD25, CD95) or survey 2
(CD45RA, CD69L, CD28, HLA-DR) were analyzed separately.
We analyzed the results from 17 patients and 13 controls in survey
1 and 16 patients and 14 controls in survey 2 (Table 3).
NK cells were defined as CD56+ lymphocytes in survey 1 and as
CD16+ lymphocytes in survey 2. The relative percentages in
patients and controls were therefore compared separately in
surveys 1 and 2. No differences were observed between patients
and control (P.0.05, data not shown).
The percentages of CD4 and CD8 T cells were similar in
patients and controls. Similar levels of T lymphocyte activation, as
shown by evaluations of CD4
+HLA-DR
+, CD8
+HLA-DR
+,
CD4
+CD69
+ and CD8
+CD25
+ cells, were observed in patients
and controls (Table 3). However, CD4
+CD25
+ T-lymphocyte
levels were significantly lower in patients than in controls
(P=0.02). The proportions of the naive CD4
+CD45RA
+ and
CD8
+CD45RA
+ T-cell subsets were similar in patients and
controls, but the proportion of naive T cells expressing CD62L
was higher in patients than in controls (P=0.03). Similarly,
patients had larger numbers of memory CD4
+CD45RA
2CD62L
+
cells (P=0.01). The pre-effector T lymphocytes populations
(CD8
+CD45RA
2CD62L
2) were of similar size in patients and
controls (Table 3), but patients had fewer effector T lymphocytes
(CD8
+CD45RA
+CD62L
2)( P=0.01).
CSF lymphocyte subset profiles and correlation with
disease stage. Logistic problems with CSF cell storage before
FC analysis resulted in some results being unexploitable. We
therefore restricted our analysis to interpretable results. We thus
present, in Table 4, only the results for B cells (CD19
+) for 4
controls, 8 S-1, 8 S-int and 13 S-2 patients. An example of the FC
images obtained is provided in Figure 2.
No B cells (CD19
+) were detected in controls (,0.01 cells/ml).
The percentages of B cells in CSF samples from controls, S-1 and
S-int patients were significantly lower than those in S-2 patients
(P,0.01). In S-2 patients, B cells accounted for 50% of the cells
present (243 cells/ml). The number of B cells increased between
control and S-1 (factor of 10), between S-1 and S-int (factor of 5)
and between S-int and stage 2 (factor of 500), although the
differences between subgroups of patients were not significantly
different.
Discussion
We provide here the first description of differences in
lymphocyte subsets in blood and CSF between HAT patients
and controls from the same ethnic group and geographic area.
Despite the preliminary nature of our results, the small sample size
and the logistic problems encountered, we identified several
interesting features consistent with known data and experimental
findings.
Patients had larger numbers of B cells (CD19
+) and activated B
cells (CD19
+CD69
+) than controls, consistent with the immune
response classically reported for HAT, with the extensive
Table 1. Clinical and epidemiological features of the subjects
studied.
Characteristics of the patients n=33
Epidemiologic
Male 19
Female 14
Age, (mean range) 32 (12–55)
Angolan origin 32
Gabonese origin 1
Active/passive screening 10/23
Clinical
Duration of signs and symptoms at enrollment 3 weeks to 3 years
Signs of hemo-lymphatic disease 18
Neurological signs 15
Sleep disturbances 11
Sensory disturbances 3
Motor disturbances 11
Psychiatric disturbances 7
Stage determination
Presence of trypanosomes in CSF 17
WBC .20 13
WBC between 5–20 9
WBC ,51 1
WBC=White Blood Cell Count in CSF.
doi:10.1371/journal.pone.0006184.t001
Lymphocyte Subsets in HAT
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amounts of antibodies [14,15]. We clearly observed an upregula-
tion of Fas (CD95) expression on the B cells of patients, consistent
with the activation of cells via CD95, which may be involved in
subsequent lymphocyte apoptosis. Cell activation seems to be self-
regulated by the increase in B-cell apoptosis, as described in T.
cruzi infection [16,17], suggesting poor conversion of B cells into
memory B cells [18]. Radwanska et al. (2008) [19] recently
demonstrated that the parasite causes a significant decrease in
various B-cell populations in mice. These changes may account for
the inability of the host to develop protective anti-parasite
antibody responses and the lack of development of an effective
B-cell memory response against parasites with variant antigens.
This strong B-cell response during infection may affect the
homeostasis of T-cell subsets. This phenomenon has been
observed in HIV infections [20,21]. HAT-infected patients have
Figure 1. Distribution of B cells (CD19
+), T cells (CD3
+), and T-cell subpopulations (CD3
+CD4
+ or CD3
+CD8
+) in the blood of 33 HAT
patients and 27 controls (surveys 1 and 2 combined). For each box plot, the features limits correspond, from bottom to top, to the 90
th,7 5
th,
50
th (median), 25
th and 10
th percentiles.
doi:10.1371/journal.pone.0006184.g001
Table 2. B cells (CD19
+) and B-cell activation markers (CD69
+
and CD95
+) in peripheral blood mononuclear cells for surveys
1 and 2.
Surface antigen Blood B cells
controls patients
n=27 n=33
CD19
+ (1) 8.762.3* 17.265.6*
n=14 n=16
(2) CD69
+ 2.461.5* 2.363.0*
CD95
+ 4.861.8* 11.363.8*
(1) n=33 patients and 27 controls from both surveys.
(2) n=16 patients and 14 controls from survey 2. Data are expressed in
percentages of total events acquired with the FACSCalibur (10
4 on
average)6standard deviation.
*Significant difference between controls and patients (P,0.05).
doi:10.1371/journal.pone.0006184.t002
Table 3. T cells subsets (CD4
+/CD8
+) and T-cell activation
markers (HLA-DR
+, CD69
+, CD25
+, CD45RA
+, CD45RA
2,
CD62L
2) in peripheral blood mononuclear cells for surveys 1
and 2.
Blood T cells
Surface antigen controls patients
n=27 n=33
CD4/CD8 (1) 1.160.8 1.360.6
n=13 n=17
CD4
+ (2) HLA-DR
+ 23.064.2 26.965.0
CD8
+ HLA-DR
+ 45.5614.8 45.9612.6
CD8
+ CD69
+ 1.260.5 1.060.4
n=14 n=16
CD4
+ (3) CD25
+ 3.061.0* 0.360.2*
CD8
+ CD25
+ 0.460.5 0.260.1
n=13 n=17
CD4
+ (2) CD45RA
+ 12.966.9 10.365.6
CD4
+CD62L
+ CD45RA
+ 19.969.0* 30.1612.8*
CD8
+ CD45RA
+ 48.3621.1 41.9615.6
CD8
+CD62L
+ CD45RA
+ 12.2611.6* 23.3612.3*
CD4
+CD62L
+ CD45RA
2 24.7612.2* 42.8615.7*
CD8
+CD62L
+ CD45RA
2 15.2612.3 21.2611.2
CD8
+ CD62L
2 CD45RA
+ 87.8611.6* 76.7612.4*
CD8
+ CD62L
2 CD45RA
2 84.8612.4 78.7611.1
(1) n=33 patients and 27 controls from both surveys.
(2) n=16 patients and 14 controls from survey 2.
(3) n=17 patients and 13 controls from survey 1. Data are expressed in
percentages of total lymphocyte events acquired with the FACSCalibur (10
4 on
average)6standard deviation.
*Significant difference between controls and patients (P,0.05).
doi:10.1371/journal.pone.0006184.t003
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CD4/CD8 ratio and an increase in the proportion of naive T
(CD62L
+CD45RA
+) cells [22]. Indeed, the CD4/CD8 ratio has
been shown to increase in autoimmune diseases and to decrease
during viral infections, but remains unaffected in HAT. Naive
lymphocytes, when stimulated by an antigen, develop into
memory lymphocytes, which subsequently differentiate into
effector lymphocytes. This process facilitates the rapid and
effective secondary response required for long-term protection of
the host [23,24]. We found that the proportion of CD8 T effector
cells (CD8
+CD45RA
+CD62L
2) was lower in patients than in
controls. Patients also had fewer CD4
+CD25
+ cells than controls,
accounting for the lower level of activation/proliferation of CD4 T
cells in patients. These findings suggest that there may be a T-cell
response dysfunction, in patients, possibly due to continuous
stimulation of the immune system by new antigenic variants from
trypanosomes, resulting in a lack of memory and effector
lymphocytes. Thus, the adaptive immune response seems to be
impaired in HAT. T cells act as effectors either through cell-
mediated cytotoxicity, following the release of dense cytoplasmic
granules containing perforin and granzymes, or through the
production of cytokines, including IFN-c in particular, thereby
activating other effector cells, such as antigen-presenting cells. On
the other hand, some of CD25-expressing T cells belong to the
Treg subset populations that represent 10% of the CD4 T cells in
humans. The natural Treg cells, CD4
+CD25
highFoxp3
+ were
recently studied in experimental model of African trypanosomiasis
in Trypanosoma congolense - infected mice [25]. This study
demonstrated that Treg cells play an important role in
trypanotolerance, through a decrease of INF-c production and
downregulation of the inflammatory response depending on IL-10
[25]. Experiment with injection of anti-CD25 on animals before
challenge, resulted in the absence of development of parasitemia
and elimination of all parasites [26].
Furthermore, the proportion of NK cells was not higher in
patients than in controls suggesting that this cell subset of innate
immune response was not modified in HAT. However, these
results require confirmation with a larger cohort and specific
markers.
Finally, the B- and T-cell subset profiles observed are consistent
with the classical immunomodulatory mechanisms described in
experimental models of HAT [27–29]. Direct (parasite-released)
and indirect (host cells) mechanisms of immunomodulation are
observed. The trypanosome-derived lymphocyte triggering factor
(TLTF), also known as trypanin, induces the production of TGF-b
mRNA in CD8 T cells and has an immunosuppressive effect [30].
In lymph node T-cell proliferation responses, the classical subset of
macrophages plays a central role in inhibiting T-cell proliferation.
Early-activated macrophages (by IFN-c activation, Th1 cytokine
pattern) inhibit T-cell proliferation most strongly, through several
mechanisms: i) the production of prostaglandin, leading to the
abolition of IL-2 production [31], ii) the induction of a
prostaglandin-independent mechanism accounting for the aboli-
tion of IL-2 receptor (IL-2R/CD25) expression [32] and iii)N O
synthesis induced by IFN-c and resulting in impaired mitogen-
induced T-cell proliferation in the spleen, peritoneal cavity and
lymph nodes of T. brucei-infected mice [33]. Later in the course of
infection, T-cell proliferation in lymph nodes may be inhibited
through other mechanisms, mediated by an NO-independent
pathway and depending on IFN-c release from CD8 T cells
[33,34]. Alternatively activated macrophages have also been
reported to play a role in experimental models of African
trypanosomiasis [12,33]. These cells are activated in the presence
of IL-4 and contribute to the development of a Th2 cytokine
pattern, which decreases inflammatory responses in the host [35].
Together, these mechanisms impair T-cell activation, resulting in
a hyporesponsiveness of T cells to parasite-related and unrelated
antigens [12,33].
We report here the first analysis of the lymphocyte subsets
expressed in patients with HAT. The relationship between
lymphocyte phenotype and final clinical outcome remains unclear,
but our results suggest that various immunosuppressive mecha-
nisms may enable parasites to evade the immune system long
Figure 2. Results of CSF analysis by flow cytometry in a HAT
patient with a cell count of 63 cells/ml.
doi:10.1371/journal.pone.0006184.g002
Table 4. B cells (CD19
+) in the CSF of HAT patients and controls.
Control group n=4 S-1 patients n=8 S-int patients n=8 S-2 patients n=13
Total CSF cell count (cells/ml) 1.761.3 2.460.9 8.361.7 477.76426.6
CD19
+ B-cell count (cells/ml) 0.0160.01* 0.1160.10¤ 0.560.36N 243.706254.26*¤N
CD19
+ B-cell % 0.760.5* 465¤ 5.965.8N 51.1623.3*¤N
HAT Patients were at stage 1 (S-1), intermediate stage (S-int) or stage 2 (S-2). B cells (CD 19
+) are expressed as means6standard deviation of absolute values and as a
percentage of total CSF cell count. Note: P,0.05 for statistical differences.
*S-2 patients vs control.
¤S-1 vs S-2 patients.
NS-int vs S-2 patients.
doi:10.1371/journal.pone.0006184.t004
Lymphocyte Subsets in HAT
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[36]. Logistic problems prevented a more comprehensive analysis
of the CSF samples, but our results for this small sample strongly
suggest that the progressive increase in the proportion of activated
B lymphocytes in the CSF may be an important indicator of stage
2 disease.
Finally, our findings provide new insight into the immunopath-
ological mechanisms underlying HAT and highlight the impor-
tance of B lymphocytes for the diagnosis of CNS invasion and
disease. B lymphocytes marked with beads coupling with anti-
CD19 can be visualized under the microscope for fresh lumbar
puncture samples, and this detection could be used in a field-
adapted diagnostic tool for determining the stage of the disease.
We are currently validating these results in a larger sample.
Materials and Methods
Subjects
The study was approved by the Angolan and Gabonese
ministries of health and was conducted in accordance with the
Helsinki declaration. Informed, written consent was obtained
from all included subjects. Subjects were selected actively, during
field surveys in Angola and Gabon, and passively, at the reference
hospitals at Viana (Angola) and N’kembo (Gabon). Two surveys
were carried out in 2002 (survey 1) and 2004 (survey 2). Patients
were selected on the basis of whole-blood screening for antibodies
with the card agglutination trypanosomiasis test (CATT) [37].
Patients were defined as subjects with a positive CATT test
confirmed by parasite detection. Controls were obtained in the
same area of endemic disease and had a negative CATT test,
with no detection of parasites in the blood after the use of
concentration techniques. Subjects presenting evidence of
coinfections (malaria, filariasis, HIV, syphilis) or under the age
of 10 years were excluded from this study. All subjects were
examined by a doctor and clinical examination findings were
noted on a case report form.
Sampling
Blood was obtained during normal diagnostic procedures. We
collected 10 ml of blood by venipuncture. The blood sample was
then divided in two, with one tube used for subtyping by
immunostaining and flow cytometry (FC) (tube containing EDTA)
and the other (tube without anticoagulant) used for serological
analysis. The storage of blood samples for FC analysis differed
between the two surveys:
- In survey 1, staining was carried out with whole blood and
monoclonal antibodies (mAbs), as described below, in the field and
was then fixed in CytocheckH (Dako France, Trappes, France) and
stored at +4uC until analysis within five days.
- In survey 2, peripheral blood mononuclear cells were isolated
in the field by density gradient centrifugation in VacutainerH
CPT
TM cell preparation tubes containing sodium heparin (Becton
Dickinson, Franklin Lakes, NJ). These cells were then frozen in the
presence of fetal bovine serum-10% dimethyl sulfoxide (Sigma-
Aldrich, Lyons, France), in liquid nitrogen.
CSF samples were obtained from patients during normal
diagnostic procedures. Four CSF samples were obtained from
patients consulting for disturbed sleep with minor neurological
signs but no detection of trypanosomes in the blood or CSF and a
normal CSF cell count. We collected 6 ml of CSF into a conical
tube. We centrifuged 4 ml of the sample and dispensed the
supernatant into aliquots, which were stored in liquid nitrogen.
The remaining 2 ml of the CSF sample was used to determine
disease stage in the field. Lumbar puncture samples containing
blood (.500 red blood cells/ml) were discarded and the patients
from whom such samples were obtained were excluded from the
study. CSF samples were immediately stained for FC, fixed with
10% CellFix (Becton Dickinson) and stored at +4uC.
Parasitological and stage determination procedures
Positive CATT results were confirmed by parasite detection in
blood or swollen lymph nodes. A modified miniature anion-
exchange centrifugation technique was used for blood [38].
Lymph nodes were punctured and the fluid obtained was observed
under the microscope.
Disease stage was diagnosed on the basis of clinical examination
and lumbar puncture. CSF was examined immediately after
puncture. Cells were counted on Kova slides (Hycor Biomedical
Inc., Gardengrove, CA). Parasite detection was carried out by
microscopic examination of 2 ml of CSF, after simple centrifuga-
tion [39].
(i) Stage 1 (S-1) was defined as the presence of fewer than
5 cells/ml in CSF, and the absence of trypanosomes on
microscopic examination.
(ii) Stage 2 (S-2) was defined as the presence of more than
20 cells/ml CSF and/or the presence of trypanosomes on
microscopic examination.
(iii) Patients were classified as having intermediate stage disease
(S-int) if their CSF profile differed from those described above - i.e,
between 5 and 20 cells/ml - or if trypanosomes were observed on
microscopy but there were fewer than 5 cells/ml CSF [40].
Clinical examination was performed jointly to confirm the
diagnosis. The detection of neurological signs in S-int patients was
indicative to treat with second stage drugs.
FC analysis
Samples were analyzed at the CIRMF in Gabon (2000 km from
the site of enrollment and sampling in Angola), within five days of
sample collection. The mAbs used were obtained from Beckman
Coulter (Fullerton, CA, USA) and Becton Dickinson (BD, Franklin
Lakes, NJ, USA) (see Table 5 and 6). The results of survey 1
determined the selection of mAbs for use in survey 2.
Fluorescence intensity was determined with a three-color
fluorescence-activated cell sorter machine (FACSCalibur, Becton
Dickinson, Franklin Lakes, NJ, USA) in survey 1 and with a four-
color machine in survey 2. Lymphocyte cells were gated on the
basis of forward and side light-scattering properties and positively
selected on the basis of cluster of differentiation (CD) molecule
expression. Isotype-matched control mAbs were used to define
background fluorescence. Before data acquisition, we checked and
optimized the instrument parameters with CaliBRITE Beads
(Becton Dickinson). On average, 10
4 events were acquired with
FACSCalibur and analyzed with CELLQUEST software (Becton
Dickinson).
During survey 1, we stained 50 ml of total blood from each
sample (using 2 ml for each antibody) within 20 minutes. The
blood sample was then lysed with a lysis buffer (8.29 g ammonium
chloride, 1 g potassium bicarbonate, 0.037 g EDTA in 1l of
distilled water, pH adjusted to 7.2), and washed twice with PBS to
select leukocytes only. During survey 2, lymphocytes (10
4) were
retrieved from frozen peripheral blood mononuclear cells by
thawing and washed in PBS. Their viability was then checked with
trypan blue and they were stained with 2 ml mAbs within 20
minutes. All samples were fixed in 4% PFA and analyzed within 5
days. For CSF, we added 2 ml of mAbs to 100 ml of CSF. We then
incubated this mixture for 15 minutes at +4uC, fixed the cells and
analyzed them within 5 days.
Lymphocyte Subsets in HAT
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The proportions (% of total events acquired) of each lymphocyte
type were calculated after acquisition on a FACSCalibur machine.
The markers used in both surveys (CD19, CD3, CD4, CD8,
CD95) were analyzed for all the patients and controls tested,
whereas markers used only in survey 1 (CD56, CD25, CD40) or in
survey 2 (CD45RA, CD69L, CD28, CD16, HLA-DR) were
analyzed separately. Due to the small sample size, the Mann-
Whitney non parametric U test was used for comparisons, with P
values below 0.05 considered statistically significant.
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